Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

Zanubrutinib is a highly selective second-generation BTK inhibitor developed in China and first approved by the U.S. Food and Drug Administration (FDA) as a novel antineoplastic drug. In recent years, with the birth of molecularly targeted drugs, the treatment of B-cell lymphoma have entered the era of targeted therapy, and immunotherapy has been widely accepted. Especially in some relapsed and refractory lymphomas, zanubrutinib has shown deep and sustained remissions and a favorable safety, which lays a foundation for precision therapy. In this review the clinical application and new progress for zanubrutinib in B-cell lymphoma was summarized briefly.


Xiao Tang, Wen-Rong Zou, Peng Peng, Yang-Lyu Bai. Clinical Application of Zanubrutinib in B-Cell Lymphoma --Review]. Zhongguo shi yan xue ye xue za zhi. 2022 Jun;30(3):965-969

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 35680835

View Full Text